Clinical Trial Update: Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial assessing adding SNDX-5613 to standard daunorubicin/cytarabine chemotherapy for newly diagnosed acute myeloid leukemia patients with NP…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Acute Myeloid Leukemia with Kmt2a Rearrangement
• Acute Myeloid Leukemia with Npm1 Mutation

Drugs mentioned

• SNDX-5613

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Acute Myeloid Leukemia With KMT2A Rearrangement, Acute Myeloid Leukemia With NPM1 Mutation | Phase 1 | Status: RECRUITING